Occam's razor…I am increasingly settled on the notion that this titrate to suppress price action has one logical source. You can fill in the blank for the source of that suppression but I don’t think it’s your usual short interest opportunist…there is little to no money to be had shorting at these levels and the borrow rates are injurious to that strategy, unless you are some entity with legitimate business interests in the pharmaceutical space. That entity does not likely care about making money shorting the stock, and is not deterred by the borrow rates. They make money on the strength of acquisition and the titrate to suppress is a business cost with a promising return.

Know what you own. We are not adrift in the Sargasso Sea never to be heard from again. I suspect there is a poker game going on in the back room. We are “all in” but by proxy, some with pretty sizable mounds of chips. Collectively with all the potential indications for this platform molecule Cytodyn you can argue is holding a full house. Some entity with I suspect occult connections to a hedge fund or operator is bluffing. Cytodyn sees the bluff and is raising.

This poker game playing out by the Quiet Company should come to an end, hopefully soon.